Effect of follow-up time on the ability of subcutaneous epcoritamab to induce deep and durable complete remissions in patients with relapsed/refractory large B-cell lymphoma: Updated results from the pivotal EPCORE NHL-1 trial.

Lunenburg Lymphoma Phase I II

Research output: Contribution to journalMeeting Abstractpeer-review

Original languageEnglish
Number of pages1
JournalJournal of Clinical Oncology
Volume41
Issue number16
Publication statusPublished - 1 Jun 2023

Cite this